Targeting CDK4 and CDK6 in cancer
S Goel, JS Bergholz, JJ Zhao - Nature Reviews Cancer, 2022 - nature.com
Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …
transition into S phase and are important for the initiation, growth and survival of many …
Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future
D Akhoundova, MA Rubin - Cancer Cell, 2022 - cell.com
Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …
through the identification of therapeutic targets and molecular biomarkers, leading to the …
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …
tumours. However, only a few patients respond to ICIs, which has generated considerable …
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
AC Watt, S Goel - Breast Cancer Research, 2022 - Springer
Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an
established standard of care for patients with advanced hormone receptor-positive breast …
established standard of care for patients with advanced hormone receptor-positive breast …
Cancer takes many paths through G1/S
ES Knudsen, AK Witkiewicz, SM Rubin - Trends in Cell Biology, 2023 - cell.com
In the commonly accepted paradigm for control of the mammalian cell cycle, sequential
cyclin-dependent kinase (CDK) and cyclin activities drive the orderly transition from G1 to S …
cyclin-dependent kinase (CDK) and cyclin activities drive the orderly transition from G1 to S …
VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4/6 inhibitors–efficacy, safety, and biomarker …
Purpose: Despite promising activity in hematopoietic malignancies, efficacy of the B-cell
lymphoma 2 (BCL2) inhibitor venetoclax in solid tumors is unknown. We report the …
lymphoma 2 (BCL2) inhibitor venetoclax in solid tumors is unknown. We report the …
INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors
Abstract Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving
proliferation of certain cancers, including those harboring CCNE1 amplification and breast …
proliferation of certain cancers, including those harboring CCNE1 amplification and breast …
[HTML][HTML] Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression
The interaction of RB with chromatin is key to understanding its molecular functions. Here,
for first time, we identify the full spectrum of chromatin-bound RB. Rather than exclusively …
for first time, we identify the full spectrum of chromatin-bound RB. Rather than exclusively …
Allelic imbalance of chromatin accessibility in cancer identifies candidate causal risk variants and their mechanisms
While many germline cancer risk variants have been identified through genome-wide
association studies (GWAS), the mechanisms by which these variants operate remain …
association studies (GWAS), the mechanisms by which these variants operate remain …
CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions
JS Lee, H Hackbart, X Cui, Y Yuan - International Journal of Molecular …, 2023 - mdpi.com
The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has
revolutionized the treatment landscape for hormone receptor-positive breast cancer. These …
revolutionized the treatment landscape for hormone receptor-positive breast cancer. These …